In one of two trials that substantially expand clinical evidence with myosin inhibitors in the treatment of hypertrophic cardiomyopathy (HCM), a next-in-class agent beat beta-blockers in first-line ...
MINNEAPOLIS — Readouts of data on an experimental drug for hypertrophic cardiomyopathies showed the agent appeared safe and effective in long-term treatment and can significantly improve exercise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback